The ClinGen Epilepsy Gene Curation Expert Panelâ  Bridging the divide between clinical domain knowledge and formal gene curation criteria by Helbig, Ingo et al.
Received: 3May 2018 Revised: 1 August 2018 Accepted: 28 August 2018
DOI: 10.1002/humu.23632
S P E C I A L A RT I C L E
The ClinGen Epilepsy Gene Curation Expert Panel—Bridging
the divide between clinical domain knowledge and formal gene
curation criteria
IngoHelbig1,2 Erin Rooney Riggs3 Carrie-Anne Barry3 KarlMartin Klein4,5
David Dyment6 Courtney Thaxton7 Bekim Sadikovic8 Tristan T. Sands9
Jacy L.Wagnon10 Khalida Liaquat11 Maria Roberta Cilio12 GhaydaMirzaa13,14
Kristen Park15 Erika Axeen16 Elizabeth Butler17 TanyaM. Bardakjian18
Pasquale Striano19 Annapurna Poduri20 Rebecca K. Siegert21 AndrewR. Grant21
Katherine L. Helbig1 Heather C.Mefford22
1Division ofNeurology, Children'sHospital of Philadelphia, Philadelphia, Pennsylvania, USA
2Department ofNeuropediatrics, Christian-Albrechts-University of Kiel, Kiel, Germany
3Autism&DevelopmentalMedicine Institute, GeisingerHealth System, Lewisburg, Pennsylvania, USA
4Department ofNeurology, EpilepsyCenter Frankfurt Rhine-Main, GoetheUniversityFrankfurt amMain, Frankfurt, Germany
5Department ofNeurology, EpilepsyCenterHessen, PhilippsUniversity,Marburg,Marburg, Germany
6Children'sHospital of EasternOntario Research Institute, University ofOttawa,Ottawa, Canada
7Department ofGenetics, University ofNorthCarolina, ChapelHill, NorthCarolina, USA
8Department of Pathology and LaboratoryMedicine,WesternUniversityMolecularGenetic Laboratory, LondonHealth Sciences, London,Ontario, Canada
9Division of ChildNeurology, ColumbiaUniversityMedical Center, NewYork, NewYork, USA
10Department ofHumanGenetics, University ofMichigan, AnnArbor,Michigan, USA
11QuestDiagnostics, AthenaDiagnostics,Marlborough,Massachusetts, USA
12Departments of Pediatrics andNeurology, University of California, San Francisco, California, USA
13Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle,Washington, USA
14Department of Pediatrics, University ofWashington, Seattle,Washington, USA
15Department of Pediatrics andNeurology, University of Colorado School ofMedicine, Aurora, Colorado, USA
16Department ofNeurology, University of Virginia, Charlottesville, Virginia, USA
17GeneDx, Gaithersburg,Maryland, USA
18Department ofNeurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
19Pediatric Neurology andMuscularDiseasesUnit, DINOGMI-Department ofNeurosciences, Rehabilitation,Ophthalmology, Genetics,Maternal andChildHealth, “G.
Gaslini” Institute, University ofGenoa, Genova, Italy
20EpilepsyGenetics Program,Department ofNeurology, BostonChildren'sHospital, Boston,Massachusetts, USA
21Laboratory forMolecularMedicine, PartnersHealthcare PersonalizedMedicine, Cambridge,Massachusetts, USA
22Division ofGeneticMedicine, University ofWashington, Seattle,Washington, USA
Correspondence
IngoHelbig,DivisionofNeurology,Children's
Hospital ofPhiladelphia, 3401CivicCenterBlvd,
Philadelphia, PA19104,USA.
Email: helbigi@email.chop.edu
Funding information
NationalHumanGenomeResearch Institute,
Grant/AwardNumbers:U41HG006834 (Rehm),
U41HG009650 (Berg), 01HG007437 (Berg)
For theClinGen/ClinVarSpecial Issue
Abstract
The field of epilepsy genetics is advancing rapidly and epilepsy is emerging as a frequent indica-
tion for diagnostic genetic testing. Within the larger ClinGen framework, the ClinGen Epilepsy
GeneCurationExpertPanel is taskedwith connecting two increasingly separate fields: thedomain
of traditional clinical epileptology, with its own established language and classification criteria,
and the rapidly evolving area of diagnostic genetic testing that adheres to formal criteria for
gene and variant curation. We identify critical components unique to the epilepsy gene curation
effort, including: (a) precise phenotype definitions within existing disease and phenotype ontolo-
gies; (b) consideration ofwhen epilepsy should be curated as a distinct disease entity; (c) strategies
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for gene selection; and (d) emerging rules for evaluating functional models for seizure disorders.
Given that de novo variants play a prominent role in many of the epilepsies, sufficient genetic evi-
dence is often awarded early in the curation process. Therefore, the emphasis of gene curation
is frequently shifted toward an iterative precuration process to better capture phenotypic asso-
ciations. We demonstrate that within the spectrum of neurodevelopmental disorders, gene cura-
tion for epilepsy-associated genes is feasible and suggest epilepsy-specific conventions, laying the
groundwork for a curation process of all major epilepsy-associated genes.
K EYWORDS
ClinGen/Clinical Genome Resource, clinical validity, epilepsy, epileptic encephalopathy, gene–
disease association
1 BACKGROUND
Epilepsy is one of the most common brain disorders, affecting up to
3 million people in the United States with an annual cost to the U.S.
healthcare system of up to 15 billion USD. Despite the availability of
a growing number of antiepileptic medications, up to 30% of persons
with epilepsy have treatment-resistant seizures, significantly impact-
ing quality of life and putting patients at risk for various comorbidi-
ties and complications including death (Moshe, Perucca, Ryvlin, & Tom-
son, 2015). Epilepsy can develop in the setting of structural changes
to the brain such as injuries or malformations. However, in a signif-
icant proportion of patients, no structural alterations can be identi-
fied through neuroimaging (Thomas & Berkovic, 2014). Twin studies
demonstrate a strong genetic contribution to various epilepsy types,
and family studies suggest a strong genetic influence on a popula-
tion level (Berkovic, Howell, Hay, & Hopper, 1998; Peljto et al., 2014;
Vadlamudi et al., 2004). Novel technologies to generate large-scale
genetic data have led to various breakthroughs in rare pediatric epilep-
sies, where precision medicine approaches are already applied (Allen,
Berkovic, Cossette, Delanty, & Winawer, 2013 EpiPM Consortium,
2015; EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome
Project, & Epi4K Consortium, 2017; Reif, Tsai, Helbig, Rosenow, &
Klein, 2017).
With the advent of next-generation sequencing technologies, the
last decade has seen an explosion of causative genes identified in
patients with epilepsy and neurodevelopmental disorders, and cur-
rently more than 40 genes are considered bona fide causes of genetic
epilepsies, given that pathogenic variants in these genes are identified
in patients with epilepsy on a regular basis in a clinical and research
setting. Most of these genes are linked to developmental and epilep-
tic encephalopathies, severe epilepsies with an early age of onset, and
multiple associated comorbidities. The genetic testing landscape is
extremely diverse ranging from targeted testing including single gene
assays to exome or genome sequencing. Targeted epilepsy gene panel
approaches are equally diverse, with some focusing on bona fide genes
causing primary epilepsy and other larger gene panels often includ-
ing genes related to syndromic disorders or candidate genes related to
epilepsy due to their cellular and functional roles.
Given that epilepsy is a dynamic disease occurring over time, it is
the hope in the field that genetic findings can be used to guide therapy
and improve patient outcomes (EpiPM Consortium, 2015). However,
using genetic data for patient treatment requires that genetic findings
are systematically vetted for the association with a given disease
entity. Although scientific publications on gene discovery have a
focus on novelty, there are few mechanisms to track the emerging
evidence for genes over time and to systematically assess their validity
within a disease context. The Clinical Genome Resource (ClinGen)
Gene Curation Expert Panel offers such a mechanism by providing an
evidence-based framework to assess the clinical validity of specific
gene–disease associations using available genetic and experimental
evidence. ClinGen is an NIH-funded initiative dedicated to identifying
clinically relevant genes and variants for use in precision medicine and
research (Rehm et al., 2015). One of the main tasks of the ClinGen
Consortium is the assessment of the validity gene–disease associ-
ations, asking the question whether variation in a certain gene has
sufficient evidence to be considered causative for a particular phe-
notype. To this end, the ClinGen Consortium has developed a formal
framework to evaluate genetic and experimental evidence supporting
or disputing a gene–disease relationship (Strande et al., 2017). This
framework will then form the basis to assess variants within these
genes based on guidelines, such as the recommendations by the
American College of Medical Genetics and Genomics (Richards et al.,
2015). Deposition of variants in curated genes in public archives such
as ClinVar (Landrum et al., 2016) will then allow variant information
to be used in diagnostic and research settings. However, prior to
considering evidence for a particular variant and considering potential
actionability of genetic testing, sufficient evidence for the involvement
of a gene within the context of a particular disease needs to be
established.
The ClinGen Epilepsy Gene Curation Expert Panel is tasked with
assessing the validity of gene–disease associations related to human
epilepsy within the formal, evidence-based gene curation framework
of the wider ClinGen Consortium, with the ultimate goal that these
findings will inform future decisions about gene selection for diagnos-
tic tests and future studies into precisionmedicine approaches. In par-
allel, the epilepsy field has a rich tradition in studying genetic causes of
human epilepsy that is traditionally focused on phenotyping. The cur-
rent manuscript describes the pilot activities during the first year of
theClinGenEpilepsyGeneCuration Expert Panel, with an emphasis on
harmonization between traditional clinical epilepsy concepts and the
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ClinGen framework to lay the groundwork for a larger gene curation
effort in the future.
2 METHODS AND RESULTS
2.1 Composition of the ClinGen Epilepsy Gene
Curation Expert Panel
The ClinGen Epilepsy Gene Curation Expert Panel has been active
since June 2017 and consists of a mixture of clinical epileptologists,
medical geneticists, genetic counselors, clinical molecular geneticists,
basic scientists, and biocurators. The composition of the working
group is international, with members from the United States, Europe,
and Canada. The ClinGen Epilepsy Gene Curation Expert Panel is
embedded within the ClinGen Neurodevelopmental Disorders Clini-
cal DomainWorking Group (CDWG) that also includes the Intellectual
Disability/AutismGeneCuration Expert Panel and theRett/Angelman-
like disorders Variant Curation Expert Panel. Two epilepsy gene spe-
cific variant curation expert panels are planned as future components
of the Neurodevelopmental Disorders CDWG including the KCNQ2
Expert Panel and the NMDA receptor Variant Curation Expert Panel
(GRIN1, GRIN2A, GRIN2B, GRIN2D). The ClinGen Epilepsy Gene Cura-
tionExpertPanel is also affiliatedwith the International Leagueagainst
Epilepsy (ILAE) Genetics Commissions through prior membership in
the Genetics Commission during the 2014—2017 term for Ingo Hel-
big and Heather Mefford and current affiliation for the 2017–2020
term through the “Epilepsiome” Task Force, linking the ClinGen gene
curation activities with the genetic literacy series of the ILAE Genet-
ics Commission (Helbig, Heinzen, Mefford, & ILAE Genetics Commis-
sion, 2016; Tan, Lowenstein, & ILAE Genetics Commission, 2015) and
peer-to-peer communication through a dedicated blog (“Beyond the
Ion Channel”; epilepsygenetics.net).
2.2 Strategies of gene selection
Within the expert panels of the Neurodevelopmental Disorders
CDWG, various strategies were used to select a set of genes for initial
curation (Figure 1). Given the frequent use of dedicated gene panels in
a clinical setting, the epilepsy expert panel decided to focus on a limited
number of genes as the first goal of gene curation, curating the “aver-
age gene panel” used in clinical practice. In order to identify commonly
tested genes, we compiled a list of 2,702 genes from 236 commercial
gene panels through a query of the Genetic Testing Registry for tests
with the keywords “seizure OR epilepsy” (Rubinstein et al., 2013). In
order to select genes with a primary epilepsy phenotype as opposed
to genes with epilepsy as a contributing feature, we compiled a con-
densed gene list of 123 genes, combining evidence from literature
(Heyne et al., 2018; Lindy et al., 2018), and expert opinion. Of this gene
list, 29 genes were selected for the pilot phase and for the precuration
process, a reviewof published phenotypes prior to initiating the formal
curation process (discussed below). Genes with primary syndromic or
nonepilepsy neurodevelopmental phenotypes including autism and
intellectual disability were excluded, such as ZEB2 for Mowat–Wilson
syndrome. In addition, genes primarily associated with a Rett-like
phenotype such asMECP2 or CDKL5were removed from the gene list,
given the existence of a dedicated working group for these conditions
within ClinGen. For some genes, an iterative review after a primary
curation has revealed that further precuration is required to deter-
mine the clinical validity of gene for a specific epilepsy phenotype (e.g.,
GRIN1). The list of precurated genes will then undergo a formal gene
curation process after selecting and possibly refining an adequate
epilepsy phenotype within the Monarch Disease Ontology (MONDO;
Figure 2). The pilot phase of the ClinGen Epilepsy Expert Panel
highlighted issues related to traditional clinical epilepsy classification
for which we developed an iterative process to systematically curate
epilepsy-associated genes, which is currently in process.
2.3 Piloting epilepsy gene curation
The ClinGen gene curation framework uses a dedicated gene curation
interface (GCI) and (MONDO for the specification of the disease entity
of interest. During the first year, an iterative process was adopted to
initiate gene curation on a few selected genes to evaluate the ClinGen
gene curation framework and its dedicated tools as they apply specif-
ically to the epilepsies. The pilot evaluation phase led to a process of
curation and precuration and an interactive process of defining the
most appropriate grouping of phenotypes for downstream gene cura-
tion. Using the previously described evidence-based framework from
the ClinGen Gene Curation Working Group (Strande et al., 2017), we
evaluated the clinical validity for the proposed gene–disease relation-
ships for 16 genes (Table 1). The ClinGen clinical validity framework
uses two main classes of available evidence, both genetic and exper-
imental, to derive a semiquantitative measurement of the strength
of the evidence for gene–disease associations. The classifications of
the strength of the gene–disease relationship include: “Definitive,”
“Strong,” “Moderate,” “Limited,” “No Reported Evidence,” and “Dis-
puted.” In order to achieve a classification of “Definitive,” a gene–
disease association must achieve at least 12 points and demonstrate
replication over time, which is defined as at least two publications
reporting pathogenic variants in the gene and at least 3 years since
the initial report. Our curation of the initial 16 genes resulted in a
classification as “Definitive” gene–disease association in seven of 16
genes, “Strong” in one of 16 genes, “Limited” in three of 16 genes, and
“Disputed” in five of 16 genes (Table 1).
2.4 Genetic evidence
Within the ClinGen gene curation framework, genetic evidence is
derived from publicly available data describing variants in the gene
of interest identified in patients with the disease entity of interest.
Genetic evidence is divided into two categories: (a) case-level data,
in which studies report individuals or families with genetic variants;
and (b) case-control data, which is derived using statistical analyses in
case-control studies. A maximum score of 12 points can be achieved
through genetic evidence, with points awarded for variant segrega-
tion and type for case-level data, and methodology, statistical power,
bias and confounding factors, and statistical significance for case-
control data. Inheritance pattern within reported cases is a strong
consideration when assessing available case-level genetic evidence,
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F IGURE 1 Gene selection and precuration process within the ClinGen Epilepsy Gene Curation Expert Panel. Starting with a broad candidate list
of genes compiled from genes available on commercial gene panel (n= 2,702), the possible candidate genes are narrowed down and supplemented
by genes with diagnostic relevance, genes with statistical evidence, and genes suggested by expert opinion. This selection process provides a
narrower list of candidate genes, including 123 candidate genes as of April 2018. This list of candidates is dynamic andmay integrate further
genes once evidence for these genes arises. From the 123 candidate genes, 29 genes were selected for the pilot phase of the ClinGen Epilepsy
Gene Curation Expert Panel for an iterative precuration process, during which the phenotypic spectrum of genes was reviewed. Genes with
primary phenotypes reviewed in other working groups or expert panels were excluded and genes with dual phenotypes were selected to be
curated for a primary epilepsy phenotype. These genes are then carried forward for a standard ClinGen gene curation process. During the pilot
phase, a small selection of genes was chosen to refine rules for genetic and experimental evidence and selection and, if necessary, modification of
Monarch DiseaseOntology (MONDO) terms
and in this regard the underlying genetic architecture of early-life
epilepsies,with a strong contribution of de novo variants, lends itself to
achieving a highnumber of points for case-level genetic evidence. Eight
of 16 genes in our pilot curation phase achieved maximum genetic evi-
dence of 12 points within the existing ClinGen gene curation frame-
work, which suggests that sufficient genetic evidence according to
ClinGen criteria is easily achieved both for well-established genetic
causes of epilepsy including SCN8A and KCNQ2 and more recently
implicated genes such as KCNA2 and ALG13 (Supporting Information
Table 1). However, we also identified eight genes with limited or dis-
puted evidence, suggesting that some of the genes traditionally con-
sidered genetic etiologies for epilepsy have limited or even contradic-
tory evidence. For example, genes such as EFHC1 or CACNA1H are dis-
puted by formal ClinGen criteria, despite the fact that these genes are
part of currently available diagnostic gene panels (EFHC1 n = 33 gene
panels; CACNA1H n = 13 gene panels). Most genetic epilepsies have
been described within the last 5 years in next-generation sequencing
studies, allowing for comparison of variant frequencies in patientswith
population databases such as ExAC and gnomAD (Lek et al., 2016),
which can be used as control populations for severe early-onset epilep-
sies. Therefore, minor allele frequencies in control populations, seg-
regation, and absence of other explanatory genetic etiologies are fre-
quently available and not a limiting factor in assessing gene validity
within the epilepsies.Within the context of the traditional clinical con-
cept of genetic epilepsies, the existing ClinGen clinical validity criteria
were found to be adequate and to be reflective of the general consen-
sus in the epilepsy field.
During our initial pilot curation phase, the expert panel noted that
within the epilepsies, the development of gene-specific assessment cri-
teria may be helpful, both for gene curation and variant interpreta-
tion. For example, a majority of known genetic epilepsies are consid-
ered “channelopathies,” resulting frompathogenic variants in neuronal
ion channel encoding genes, oftenwith a gain-of-function effect (Oyrer
et al., 2018). Consequently, loss-of-function variants, which are typi-
cally considered damaging or pathogenic in most genes, may actually
be tolerated in many neuronal ion channels or result in milder pheno-
types, as is the case in KCNQ2 (Miceli et al., 1993). Domain knowledge,
bothof expected clinical phenotypes for genetic epilepsy syndromes as
well as expected variants and functional consequences, is essential in
appropriately interpreting the significance of epilepsy-associated vari-
ants. A future goal of theClinGenEpilepsyGeneCuration Expert Panel
is to develop gene-specific assessment criteria in the context of the
epilepsies, taking these and other considerations into account, which
will aid in curation both of gene-disease associations as well as variant
interpretation.
The expert panel has not yet considered gene–disease relationships
where gene validity was primarily asserted through association stud-
ies. Evaluation of case-control data will be particularly relevant for
milder, complex genetic epilepsies including the genetic generalized
epilepsies and nonlesional focal epilepsies, where monogenic factors
play a role in a minority of patients. Future curation efforts taking into
account genetic evidence derived from case-control studies will allow
the expert panel to assess its applicability to epilepsies with a complex
underlying genetic architecture.
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F IGURE 2 Differences between theMonarch DiseaseOntology (MONDO) used in the ClinGen gene curation process and the International
League against Epilepsy (ILAE) classification, using the example of Dravet syndrome (MONDO_0011794).Within theMONDO classification, the
termDravet syndrome has both parent terms and child terms. The parent terms are different clinical and genetic concepts that comprise Dravet
syndrome as an entity, such as “Infantile Epilepsy Syndrome” (MONDO_0020071) or “Infancy Electroclinical Syndrome” (MONDO_000413). The
termDravet syndrome is synonymous with Early Infantile Epileptic Encephalopathy (EIEE), type 6 (SCN1A) and has two child terms, EIEE4
(STXBP1) and EIEE19 (GABRA1).Within the ILAE classification, seizure types, epilepsy types, and epilepsy syndromes are classified on three levels,
defining seizures types (generalized and occasional focal seizures in Dravet syndrome), epilepsy types (generalized epilepsy), and epilepsy
syndrome. The ILAE classification does not formally classify epilepsy syndromes by diagnostic criteria, but states that electroclinical syndromes
are clusters of features incorporating seizure types, EEG, and imaging features that tend to occur together, referring to the ILAE educational
resource epilepsydiagnosis.org that provides examples, diagnostic parameters, review videos of seizure types, and the EEG features of many
established syndromes, including Dravet syndrome. In addition, the ILAE classification suggests to provide an etiology for each level, including a
genetic etiology
2.5 Experimental evidence
Gene-level experimental evidence is derivedwithin theClinGen frame-
work by assessing the following types of available evidence: biochem-
ical function, experimental protein interactions, expression, functional
alteration in patient and nonpatient derived cells, phenotypic rescue,
and animal model systems (Strande et al., 2017). A maximum of six
points can be achieved from experimental evidence, taking various
factors into account including, but not limited to, the relevance and
robustness of the experimental assay. Experimental evidence in the
eight genes with strong or definite evidence assessed during the pilot
curation phase ranged from absent to the full amount of six possible
points (Table 1). Only one gene–disease association was awarded no
points for experimental evidence, due to lack of available evidence.
The remaining sevengeneswereawarded someexperimental evidence
points, ranging from two to six points. The types of experimental evi-
dence used to assess the gene–disease associations were highly vari-
able, including biochemical function, expression, functional alteration
(largely in nonpatient cells), and animal models (Supporting Informa-
tion Table 1). Although the neuroscience field has a strong tradition
of functional studies in neuronal ion channels (Oyrer et al., 2018), the
pilot curation phase did not reflect a bias toward experimental evi-
dence for ion channel genes; experimental evidence points were also
awarded for non-ion channel encoding genes including DNM1, CHD2,
and STXBP1, although notably not ALG13. However, experimental evi-
dence was not needed to obtain sufficient points for the classification
of genes as definitive or strong for any of the eight genes with strong
or definite evidence curated within our pilot phase. This indicates that
the evidence for gene validity in the epilepsy field is primarily driven
by genetic findings due to the large number of published studies and a
high proportion of genetic epilepsies due to de novo variants and thus
generally do not require experimental evidence as support.
The ClinGen gene curation framework is used as a guide, and in
certain scenarios it is appropriate for the expert panel to adjust scor-
ing or final classifications based on professional judgment. Given this
consideration and the complexity of neurodevelopmental phenotypes,
the expert panel decided to award reduced points for experimental
evidence in some scenarios. For example, for KCNA2, the main mouse
model has an ataxia phenotype but not a seizure phenotype (Xie et al.,
2010). Although ataxia is increasingly recognized as a common feature
in patients with KCNA2-related neurodevelopmental disorders, the
question arises how related phenotypic features should be scored
within the concept of primarily assessing functional evidence toward
the epilepsy phenotype. Within the working group, it was agreed
that the presence of incomplete neurological phenotypes in model
systems, which may include movement disorders, would be scored at
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TABLE 1 Curation results for 16 genes in pilot phase
Gene Disease entity
Date of
curation
Genetic
evidence
(points)
Experimental
evidence
(points) Total points
Replication
over time Classification
ALG13 Undetermined Early-Onset Epileptic
Encephalopathy
(MONDO:0018614)
3/14/18 12 0 12 Yes Definitive
CHD2 Childhood-Onset
Epilepsy Syndromea
(MONDO:0020072)
7/18/17 12 3 15 Yes Definitive
DNM1 Infantile Epilepsy Syndrome
(MONDO:0020071)
5/31/18 12 4.5 16.5 Yes Definitive
KCNQ2 Early Infantile Epileptic
Encephalopathy
(MONDO:0016021)
9/5/17 12 5.5 17.5 Yes Definitive
KCNT1 Childhood-Onset
Epilepsy Syndromeb
(MONDO:0020072)
7/26/17 12 2 14 Yes Definitive
SCN8A Infantile Epilepsy Syndromea
(MONDO:0020071)
1/6/17 12 6 18 Yes Definitive
STXBP1 Early Infantile Epileptic
Encephalopathya
(MONDO:0016021)
6/15/17 12 6 18 Yes Definitive
KCNA2 Infantile Epilepsy Syndrome
(MONDO:0020071)
10/5/17 12 4 16 No Strong
GRIN2D Infantile Epilepsy Syndrome
(MONDO:0020071)
7/3/18 3 1.5 4.5 No Limited
RYR3 Undetermined Early Onset Epileptic
Encephalopathy
(MONDO:0018614)
6/28/18 1 0 1 No Limited
SCN9A Epilepsy (MONDO:0005027) 6/15/18 3.8 0.5 4.3 No Limited
CACNA1H Generalized Epilepsy
(MONDO:0005579)
7/31/18 0 4.5 4.5 No Disputed
CACNB4 Generalized Epilepsy
(MONDO:0005579)
6/22/18 0 2 2 No Disputed
EFHC1 JuvenileMyoclonic Epilepsy
(MONDO:0009696)
7/27/18 0 1 1 No Disputed
MAGI2 Infantile Epilepsy Syndrome
(MONDO:0020071)
6/26/18 0 0.5 0.5 No Disputed
SRPX2 Rolandic Epilepsy-Speech Dyspraxia
Syndrome (MONDO:0015587)
7/19/18 0 0 0 No Disputed
aProvisionally curated for this termwith the understanding that it does not fully encompass the range of phenotypes associated with the disease; in the
future, “Complex Neurodevelopmental Disorder” will be used as disease entity.
bDuring the precuration phase, it was decided to consider Epilepsy of Infancy withMigrating Focal Seizures and Autosomal Dominant Nocturnal Frontal
Lobe Epilepsy as one disease entity, since families have been reportedwith individuals with both clinical presentations, and the same pathogenicKCNT1
variant has been associatedwith both clinical presentations. MONDO:0020072 has been used as a temporary placeholder.
0.5 compared to the default of 2 points for animal models that exhibit
spontaneous seizures.
2.6 Use of disease and phenotype ontologies
Within the ClinGen framework, curation for a gene–disease associa-
tion requires the selection of a disease entity for which a given gene
is curated. Disease entities within the ClinGen framework are coded
within the MONDO (https://www.ebi.ac.uk/ols/ontologies/mondo), an
aggregate ontology of human disease phenotypes using a hierarchi-
cal concept of parent and child terms (Figure 2). Although MONDO
includes epilepsy syndromes, the human phenotype ontology (HPO) is
an ontology of symptoms, which, in the context of epilepsies, would
include seizure types and defined comorbidities such as intellectual
disability or movement disorders. Epilepsy is a field with a rich tradi-
tion focused on electroclinical phenotyping, and the concept of using
disease and phenotype ontology is relatively new. Only some research
initiatives such as the EuroEPINOMICS-RES Consortium have consis-
tently used HPO terms and have been involved in the generation of
these ontologies (Kohler et al., 2014, 2017).
Disease and phenotype ontologies have often been generated
through a computational data aggregation process that may result
in inconsistencies with existing clinical classifications at the level of
individual disease phenotypes. We identified a lack of correspon-
dence of known disease entities in MONDO with the current and
previous ILAE classification of the epilepsies (Scheffer et al., 2017),
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indicating the need to align the MONDO with classifications that are
used clinically and in epilepsy genetics research, such as the 2017
ILAE (Figure 2). We identified concepts within the ILAE classifica-
tion that cannot be easily translated into a disease ontology primar-
ily defined by phenotypic features such as MONDO. Although many
epilepsy syndromes can be mapped onto the MONDO, the classifi-
cation of epilepsy by etiology, for instance, cannot be easily trans-
lated to the MONDO. Figure 2 demonstrates the differences in clas-
sification for Dravet syndrome (MONDO_0011794). Within the 2017
ILAE classification, seizure types, epilepsy types, and epilepsy syn-
dromes are classified on different levels, whereas the MONDO pro-
vides various parent terms for Dravet syndrome, reflecting the use
of this epilepsy syndrome in various contexts. Within the ILAE clas-
sification, epilepsy syndromes are referred to as clusters of clini-
cal, electroencephalography (EEG), or imaging features, but once a
diagnosis of a specific syndrome is made it is not defined to which
broader parent term the syndrome belongs to. However, such a
hierarchical structure is the basis of theMONDO.
2.7 Iterative curation of epilepsy-related genes
2.7.1 Precuration
In complex neurodevelopmental disorders, the review of associated
phenotypes led to an iterative process of curation including a precu-
ration step. The ClinGen Lumping and Splitting Working Group has
developed precuration guidelines that have been used by the epilepsy
expert panel in precuration efforts during our pilot phase (https://
www.clinicalgenome.org/working-groups/lumping-and-splitting/).
The precuration process includes a review of published phenotypes
prior to launching the gene curation process, leading to a possible
assertion of distinct phenotypes versus disease spectrums, which is
then substantiated or refuted during the precuration review of the
evidence for or against distinct phenotypes. For a range of disease
genes, a spectrum of disease entities has been observed, sometimes
evenwith distinct disease entities associated with identical variants.
During the curation of the 16 epilepsy-related genes and selection
of 27 additional genes for precuration in the pilot phase, we observed
that traditional clinical distinctions between known disease entities
may not necessarily apply when using the ClinGen framework for
genetic etiologies associated with epilepsy. A “variant first” approach
to lumping and splitting of epilepsy phenotypes is conceptually differ-
ent from the “phenotype first” approach in a clinical setting, and it may
not be sensitive to known distinctions between clinical entities if the
variants overlap. For example, in the case of SCN1A-related disorders,
there is a traditional clinical distinction between Dravet syndrome, a
distinct developmental and epileptic encephalopathy that presents in
the first year of life, and other forms of generalized epilepsy as amilder
phenotype (Steel, Symonds, Zuberi, & Brunklaus, 2017; Zhang et al.,
2017).However, as there are at least some families reportedwith over-
lapping phenotypes associated with the same variant (Goldberg-Stern
et al., 2014; Hoffman-Zacharska et al., 2015), SCN1A-related disorders
would be primarily considered a spectrum and would be curated for a
broad rather than narrow phenotype. Similar observations were made
for genes such as SCN2A and SCN8A. Alternatively, some gene-disease
associations emerged as distinct phenotypes that were less apparent
at the outset. For example, in ALG13, strong evidence emerged for
an epilepsy phenotype in females with a recurrent de novo variant.
However, only limited evidence arose for the congenital disorders of
glycosylation phenotype that was first described and that is consistent
with the presumed function of this gene. Due to the accrual of genetic
evidence through multiple reports, the female epileptic encephalopa-
thy phenotype that was initially considered a subphenotype has
“overtaken” the initial ALG13 phenotype with respect to gene validity.
Finally, some genes behaved as expected in the precuration process.
For example, for KCNQ2, precuration successfully identified both
the mild phenotype due to haploinsufficiency and the more severe
phenotype primarily associated with missense variants with predicted
dominant-negative effect, mirroring the separation between known
clinical entities, self-limited neonatal seizures (also known as benign
familial neonatal epilepsy), and KCNQ2 encephalopathy, within the
ClinGen precuration framework.
3 DISCUSSION
In the current manuscript, we describe the pilot phase of the epilepsy
gene curation activities within the ClinGen Epilepsy Gene Curation
Expert Panel. We demonstrate that the established gene curation pro-
cess can be applied to genetic etiologies linked to human epilepsy
with special considerations. We observe that genetic evidence for a
selection of epilepsy genes in the pilot phase can be readily provided
through the published literature. Both the de novo architecture of neu-
rodevelopmental disorders as well as the high frequency of follow-
up publications focusing on phenotype delineation contribute to this
effect.However, other genes frequently testedondiagnostic genepan-
els have contradictory evidence, and the gene–disease relationships
must be considered disputed by the formal criteria of the ClinGen
Consortium (CACNA1H, CACNB4, EFHC1,MAGI2, SRPX2). Three genes
curated within the pilot phase have limited evidence (GRIN2D, RYR3,
SCN9A), indicating thatmore evidence is needed to support a strong or
definite gene–disease association within the context of epilepsy. We
identify the appropriate selection of the disease phenotype as one of
the major challenges in the curation effort, an activity that is usually
referred to as precuration.
In contrast tomany other disease entities, the epilepsies are pheno-
types that are not easily classified within the existing ontologies and
format, requiring the ClinGen Epilepsy Gene Curation Expert Panel
to put a strong focus on the precuration effort. Given that both the
MONDO and HPO classifications are increasingly used in a diagnos-
tic context, we highlight the importance of iteratively improving exist-
ingontologies to align these classificationswith the classificationsused
in a clinical setting. In other words, classifications used for diagnos-
ing genetic epilepsies should harmonize with the schema used by the
epileptologists who treat these patients.
Within the formal ClinGen framework, assessment of gene
validity precedes the interpretation on the variant level according
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to variant classification guidelines such as the American College
of Medical Genetics and Genomics (ACMG) recommendations.
However, particularly for the well-studied ion channel genes, iden-
tified variants have been demonstrated to have variable, if not,
opposite functional effects. For example, disease-causing gain-of-
function and loss-of-function variants are observed in genes such
as SCN2A or SCN8A. This observation raises the issue whether the
variant-level interpretation can be separated from the gene-level
interpretation. The ClinGen Consortium has addressed this ques-
tion by providing recommendations on when phenotypes linked to
a particular gene should be lumped into a single phenotypic spec-
trum or split into separate phenotypes (https://www.clinicalgenome.
org/working-groups/lumping-and-splitting/). The identification of
appropriate phenotypes is part of the precuration effort, further
emphasizing the need for a detailed precuration phase for epilepsy-
related genes. We have assessed this question for SCN8A where both
gain-of-function and loss-of-function variants have been described in
the literature.Weconcluded that the SCN8A-relateddisorders demon-
strate a broad spectrum independent of the functional effect of the
variant, including variable presentations for known recurrent variants.
With increasing knowledge about different phenotypes, outcomes,
and therapeutic responses, some of the curated genes may have
sufficient evidence to be split into distinct phenotypes in the future.
Harmonizing traditional epilepsy phenotypes with the phenotypic
categories provided by the MONDO provided a particular challenge
and for some phenotypes, the existing disease ontologies were insuf-
ficient. For example, the diagnostic term Early Infantile Epileptic
Encephalopathy is increasingly used both in clinical and diagnostic
settings, but the term as defined by the MONDO disease ontology
does not match the accepted clinical definition for this term. In order
to overcome the present mismatches between existing clinical clas-
sifications and MONDO, the members of the ClinGen Epilepsy Gene
Curation Expert Panel have agreed on using specific terms such as
“Early Infantile Epileptic Encephalopathy” (MONDO ID:0016021) as
placeholder terms for agreed-upon clinical concepts such as Devel-
opmental and Epileptic Encephalopathy despite some inconsistency
of parent and child terms within the current ontology while ongoing
collaboration with the MONDO Consortium continues in order to
better define epilepsy-related syndromes that resemble existing clin-
ical classifications such as the ILAE classification within the MONDO
etiology. We recognize that the term “Epileptic Encephalopathy” as
it is used for our gene curation purposes is an imperfect placeholder
and does not reflect the full clinical spectrum of the genetic epilepsies
that have been curated, nor does it necessarily accurately reflect the
clinical concept of an epileptic encephalopathy (Howell, Harvey, &
Archer, 2016). However, given that the MONDO disease ontology
is interlinked with corresponding HPO terms that are used in many
diagnostic laboratories to define the phenotypic overlap of specific
genetic variants, aligning clinical classifications with ontologies used
in laboratory diagnostics is an important prerequisite for meaningful
gene and variant interpretation in a diagnostic setting.
The corollary of this process is that the task of the Epilepsy Gene
Curation Expert Panel is expanding, shifting from a traditional gene
curation platform to an initiative to systematize the representation
of epilepsy-related terminology in disease and phenotype ontologies
thatwill provide the basis for bioinformatic assessments of phenotypic
overlaps. The iterative process of refining ontological entities prior to
gene curation is unique to the ClinGen Epilepsy Gene Curation Expert
Panel and reflects the traditional focus on phenotyping within the
epilepsy field.
Going forward, the ClinGen Epilepsy Gene Curation Expert Panel
will curate all major genes related to human epilepsies in a systematic
fashion to suggest gene-specific variant curation criteria that will help
reduce the high burden of variants of uncertain significance. This will
aid the ultimate goal of providing a framework for accurately assessing
variant pathogenicity for future precisionmedicine interventions.
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